NCT05338489View on ClinicalTrials.gov

A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

May 11, 2018

Primary Completion Date

July 28, 2018

Study Completion Date

August 22, 2018

Conditions

Healthy

Interventions

DRUG

Selpercatinib

Administered orally.

DRUG

Itraconazole

Administered orally.

DRUG

Rifampin

Administered orally.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Collaborators (1)

Loxo Oncology, Inc.

All Listed Sponsors

collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT05338489 - A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants | Biotech Hunter | Biotech Hunter